Ranbaxy to soon supply anti-ulcer drug Nexium’s low-cost version

Ranbaxy Laboratories expects to start supplying a low-cost version of anti-ulcer drug, sold under the brand Nexium by AstraZeneca to the British drugmaker, towards the end of 2011. The drugmaker had entered into an agreement three years ago to supply a cheap version of the drug to Astra-Zeneca starting May 2010, that could fetch $40-50 million in annual revenues for Ranbaxy. The supply has been delayed due to pending approvals from the American drug regulator as the medicine is to be sold by AstraZeneca in the US.crackcrack